Richard A. Fair
CEO, President & DirectorMr. Richard A. Fair, also known as Rick, M.B.A., is CEO, President & Director of Enliven Therapeutics, Inc. from December 11, 2025. Mr. Fair, has experience in product development and commercialization, including many years with large pharmaceutical companies. Mr. Fair has been an Independent Director of Clovis Oncology, Inc since October 11, 2018. He served as Chief Executive Officer and President of Bellicum Pharmaceuticals, Incorporated since January 31, 2017 until June 30, 2023 and serves as its Director since February 23, 2024. Mr. Fair served as Head of Oncology Global Product Strategy and Senior Vice President at Genentech, Inc. from January 2014 until January 31, 2017. He served as Senior Vice President, Therapeutic Head Oncology Global Product Strategy at Genentech, Inc. a subsidiary of Roche Holding AG. He served as Vice President of Sales and Marketing for Targeted Small Molecule Franchise at Genentech, Inc. From April 2006 to January 2014, he held other positions at Genentech, including Vice President, Global Product Strategy Hematology & Signaling from November 2012 through December 2013 and Vice President, Sales & Marketing, Oral Oncolytics, from May2010 to November 2012. Mr. Fair led oncology product strategy and global commercialization, overseeing the launch of five new molecular entities, including TECENTRIQ?, the first immunotherapy approval for patients with advanced bladder cancer and numerous line extensions. He also contributed to a substantial expansion of investment into cancer immunotherapy and precision medicine. Previously, he held several commercial leadership positions within Genentech, including franchise leadership with P&L responsibility for its thrombolytics and oral oncolytics businesses. Prior to Genentech, he spent many years in the pharmaceutical business at Johnson & Johnson, holding leadership roles in marketing, managed care and reimbursement strategy and managed care customer management. Mr. Fair holds a Bachelor of Science from the University of Michigan and a Masters of Business Administration from Columbia University.
Positions
- Company NameEnliven Therapeutics, Inc.Stock CodeELVNPositionCEO, President & DirectorColleagues
- SSSamuel S. KintzCo-Founder & Head of Pipeline
- BHBenjamin HohlCFO & Head of Corporate Development
- HLHelen Louise CollinsChief Medical Officer
- JPJoseph P. LyssikatosCo-Founder & Research Fellow
- RGRishi GuptaIndependent Director
- JBJacob B. BauerIndependent Director
- SGScott GarlandDirector
- MKMika Kakefuda DerynckIndependent Director
